

# Comparison of Efficacy of Three Different Anti-Vascular Endothelial Growth Factor Agents in Treatment of Macular Edema Secondary to Branch Retinal vein Occlusion

## Retinal Ven Dal Tıkanıklığına Bağlı Maküla Ödeminin Tedavisinde Üç Farklı Anti Vasküler Endotelyal Büyüme Faktörünün Etkinliğinin Karşılaştırılması

Havva KALDIRIM<sup>1</sup>, Ahmet KIRGIZ<sup>1</sup>, Kürşat ATALAY<sup>1</sup>, Şenay AŞIK NACAROĞLU<sup>1</sup>

### ABSTRACT

**Purpose:** To compare the efficacy of intravitreal anti-vascular endothelial growth factor (VEGF) agents for the treatment of macular edema (ME) following branch retinal vein occlusion (BRVO).

**Materials and Methods:** Totally 69 eyes of 69 patients with macular edema secondary to non-ischemic BRVO were retrospectively reviewed. Totals of 27 patients treated with intravitreal bevacizumab (IVB), 22 with intravitreal ranibizumab (İVR), and 20 with intravitreal aflibercept (İVA) were included in the study. Best corrected visual acuity (BCVA), central macular thickness (CMT) and intraocular pressure (IOP) measurements were reviewed at months 1, 3, 6, 9 and 12 months after treatment.

**Results:** BCVA was significantly better in İVR and İVA groups, compared with the IVB group at 6 month 6 (p=0.002). Similarly, CMT was significantly lower in İVR and İVA groups, at month 6 (p=0.001). Regarding BCVA, CMT and IOP values at month 12, there was no significant difference between groups (p=0.72, p=0.34, p=0.40, respectively). The mean number of injections was significantly higher in IVB group while significantly lower in İVA group (4.70±1.10, 3.40±0.50, p=0.001, respectively).

**Conclusion:** All three anti-VEGF agents found to be effective in the treatment of ME after BRVO. Total number of injection was significantly lower in İVA group than other 2 groups.

**Key Words:** aflibercept, bevacizumab, branch retinal vein occlusion, macular edema, ranibizumab.

### ÖZ

**Amaç:** Retinal ven dal tıkanıklığına (RVDT) bağlı maküla ödemi tedavisinde anti vasküler endotelyal büyüme (VEGF) faktörlerinin etkinliğini araştırmak

**Gereç ve Yöntemler:** İskemik olmayan RVDT'ye bağlı maküla ödemi olan 69 hastanın 69 gözü geriye dönük olarak incelendi. Çalışmaya, intravitreal bevacizumab (İVB) ile tedavi edilen 27 hasta, intravitreal ranibizumab (İVR) ile tedavi edilen 22 hasta ve intravitreal aflibercept (İVA) ile tedavi edilen 20 hasta dahil edildi. Tedaviden sonra 1., 3., 6., 9. ve 12. aylarda en iyi düzeltilmiş görme keskinliği (EİDGK), merkezi maküla kalınlığı (MMK) ve göz içi basıncı (GİB) ölçümleri kaydedildi.

**Bulgular:** EİDGK, İVR ve İVA gruplarında 6. ayda İVB grubuna göre anlamlı olarak daha iyiydi (p = 0,002). Benzer şekilde, MMK 6. ayda İVR ve İVA gruplarında anlamlı olarak daha düşüktü (p = 0,001). EİDGK, MMK ve GİB değerlerinin 12. ay sonuçları ile ilgili olarak gruplar arasında istatistiksel olarak anlamlı fark yoktu (sırasıyla p = 0,72, p = 0,34, p = 0,40). Ortalama enjeksiyon sayısı İVB grubunda anlamlı olarak yüksek, İVA grubunda ise anlamlı derecede düşüktü (sırasıyla 4,70 ± 1,10, 3,40 ± 0,50, p = 0,001).

**Sonuç:** Her üç anti VEGF ajanı RVDT sonrasında gelişen maküla ödemi tedavisinde etkili bulundu. Toplam enjeksiyon sayısı İVA grubunda diğer iki gruba göre anlamlı olarak düşüktü.

**Anahtar Kelimeler:** aflibercept, bevacizumab, makuler ödem, ranibizumab, retinal ven dal tıkanıklığı.

1- Uz. Dr., Sağlık Bilimleri Üniversitesi, Bağcılar Eğitim ve Araştırma Hastanesi, Göz Kliniği, İstanbul, Türkiye

Geliş Tarihi - Received: 04.01.2018

Kabul Tarihi - Accepted: 07.05.2018

Ret-Vit 2019; 28: 56-61

Yazışma Adresi / Correspondence Address:

Ahmet KIRGIZ

Sağlık Bilimleri Üniversitesi, Bağcılar Eğitim ve Araştırma Hastanesi, Göz Kliniği, İstanbul, Türkiye

Phone: +90 212 440 4000

E-mail: ahmetk1@yahoo.com

## INTRODUCTION

Branch retinal vein occlusion (BRVO) is a common sight-threatening retinal vascular disorder; in which macular edema (ME) is the main cause of visual impairment.<sup>1</sup> Retinal ischemia after vascular occlusion can cause elevations in both vitreous and aqueous vascular endothelial growth factor (VEGF) levels.<sup>2,3</sup> Increased VEGF levels result in higher vascular permeability and associated ME in patients with BRVO. For many decades, the treatment for BRVO has been directed by the pivotal Branch Vein Occlusion Study (BVOS),<sup>4</sup> which suggested grid-pattern laser photocoagulation for angiographic perfusion of ME as a standard of care for selected eyes that do not exhibit spontaneous resolution within 3 months of onset. However, in recent years, there has been significant advancement in the pharmacotherapy for ME associated with BRVO. Inhibitors of VEGF, also known as anti-VEGFs, have revolutionized the treatment of ME associated with BRVO.

Intravitreal injections of anti-VEGF, such as bevacizumab (Avastin™, Genentech Inc., South San Francisco, CA, USA), ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) and aflibercept (Eylea™, Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA, and Bayer Pharma AG, Berlin, Germany), can effectively lower intraocular level of VEGF and reduce vascular permeability related to ME in BRVO.<sup>5-7</sup> Although the data about the efficacy of intravitreal anti-VEGF in ME associated with BRVO is accumulating, to the best of our knowledge, studies comparing these agents is lacking in the literature. Herein, we performed a study comparing the efficacy of intravitreal bevacizumab (IVB), intravitreal ranibizumab (IVR) and intravitreal aflibercept (IVA) treatments for ME following BRVO.

## MATERIALS AND METHODS

### *Patient Selection*

The study was conducted in accordance to Declaration of Helsinki. The study was approved by the local research ethics committee of Bagcilar Training and Research Hospital. Overall, 69 eyes of 69 patients with ME secondary to non-ischemic BRVO were retrospectively reviewed. All patients included have no history of intravitreal anti-VEGF injection, macular laser (grid or focal) or other associated treatments. Patients who were previously diagnosed to have diabetic retinopathy, vitreomacular traction or epiretinal membrane were excluded. The patients with non-ischemic BRVO were diagnosed with a retinal non-perfusion area less than 5 disc diameters by fluorescein angiography (FA). Macular edema was defined as macular leakage on FA and central macular thickness (CMT) of more than 300 µm detected by spectral-domain optical coherence tomography (SD-OCT) scans (Retinascan RS-3000; NIDEK,

Gamaori, Japan) through the fovea in all patients. Baseline best-corrected visual acuity (BCVA) using the Snellen chart (converted into logMAR for statistical comparison), intraocular pressure (IOP) via pneumotonometer (CT-80, Topcon, Tokyo, Japan), and biomicroscope of anterior segment were examined in all patients. Once the patients were diagnosed with ME secondary to BRVO; IVB, IVR or IVA treatments were administered within one week. From January 2014 to December 2016, consecutively 27 patients treated with loading dose (monthly, 3 injections) followed by pro-re-nata (PRN) IVB (1.25mg/0.05mL), 22 patient treated with 3+PRN IVR (0.5mg/0.05 mL) and 20 patient treated with 3+PRN IVA (2mg/0.05 mL) were included in the study.

### *Intravitreal Treatment Technique and Data Acquisition*

Following topical anesthesia and disinfection of eyelid and conjunctiva, bevacizumab, ranibizumab or aflibercept was injected into the vitreous cavity using a 30-gauge needle inserted through the superotemporal pars plana, 3.5-4 mm posterior to the limbus. After the procedure, 0.5% moxifloxacin dropped into the conjunctival sac. The eye was patched for two hours. The patch was removed; then patients were instructed to instill one drop of 0.5% moxifloxacin into the injected eye five times daily for five days.

All patients were followed up at month 1, 3, 6, 9 and 12, with the anterior segment and fundus examination and BCVA, CMT, and IOP measurements. At the end of month 6, a control FA was performed to all patients; and, in patients who showed ischemia larger than 5 optic discs at FA, a scatter laser was performed to the ischemic areas. In the first year of follow-up, no grid or focal macular laser was performed in our cases. The follow-up SD-OCT scans were assessed by using the baseline scan as a reference. Visual testing was done in the same room at each visit. Re-treatment was based on findings of SD-OCT including CMT more than 300 µm, or presence of persistent or recurrent macular cysts or sub-macular fluid affecting the visual acuity even if CMT is less than 300 µm. Primary outcome measures included alterations in CMT and BCVA at month 12 during follow-up. Complications after injections were recorded.

### *Statistical Analysis*

All analyses were performed using the Statistical Package for Social Sciences (SPSS) for Windows 21.0 program. Descriptive statistics were used for analyses of demographic data. Comparisons of mean values of BCVA, CMT and IOP at different time periods of different treatment groups were performed with Student's t test. Demographic data and treatment results of 3 different subgroups were performed with Chi-square test and one-way Anova with post-hoc Tukey test. Results were expressed as mean ± S.D. A p value of <0.05 was considered as statistically significant.

## RESULTS

The study was performed on 69 eyes of 69 patients (29 female [42%], 40 male [58%]; mean age of 69.91± 4.32 years) with ME secondary to BRVO. Among 69 patients, 27 were in IVB group, 22 were in IVR

group and 20 were in IVA group. Table 1 shows some of the demographic data of the patients and includes periods between symptom onset and first intravitreal injection (pre-treatment period). There was no statistically significant difference in pretreatment values of BCVA, IOP or CMT among groups (Table 2 and 3). The

**Table 1.** Comparison of demographic features of treatment groups.

	Bevacizumab Group (IVB) (n:27)	Ranibizumab Group (IVR) (n:22)	Aflibercept Group (IVA) (n:20)	p
Age (years)	69.19 ±4.67	70.32 ±4.30	70.45± 3.89	0.54
Gender (F/M)	13/14	8/14	8/12	0.69
Pre-treatment period (months)	2.55 ± 0.51	2.54 ± 0.50	2.65± 0.49	0.76
Injection number	4.70± 1.10	4.05± 0.99	3.40± 0.50	<b>0.001</b>

p: One way ANOVA

**Table 2.** Comparison of best corrected visual acuity and central macular thickness of treatment groups.

	Bevacizumab Group (IVB) (n:27)	Ranibizumab Group (IVR) (n:22)	Aflibercept Group (IVA) (n:20)	p <sup>1</sup>
Pre-BCVA	0.62± 0.14	0.64 ±0.13	0.66±0.14	0.66
Post-BCVA-month 1	0.33±0.11	0.32± 0.12	0.29 ±0.09	0.46
Post-BCVA-month 3	0.30±0.13	0.25±0.09	0.25± 0.08	0.15
Post-BCVA-month 6	0.35± 0.15	0.24± 0.11	0.23±0.09	<b>0.002</b>
Post-BCVA-month 9	0.30± 0.09	0.27± 0.12	0.26± 0.09	0.48
Post-BCVA- month 12	0.29± 0.09	0.27± 0.14	0.26± 0.08	0.72
p <sup>2</sup>	<b>0.001</b>	<b>0.001</b>	<b>0.001</b>	
Pre-CMT	472.07±88.94	496.18±99.98	491.60±97.89	0.64
Post-CMT-month1	306.74±39.43	300.59±36.26	297.45±29.69	0.66
Post-CMT-month 3	293.89 ±37.12	281.82±40.59	268.80±29.86	0.07
Post-CMT-month 6	325.89 ±52.65	288.77±48.08	265.75±29.66	<b>0.001</b>
Post-CMT-month 9	284.63± 31.79	287.59±44.47	279.90±32.88	0.79
Post-CMT-month 12	286.89± 28.92	280.45±45.98	271.05±33.69	0.34
p <sup>2</sup>	<b>0.001</b>	<b>0.001</b>	<b>0.001</b>	


IVB: Intravitreal bevacizumab, IVR: Intravitreal ranibizumab, IVA: Intravitreal aflibercept, BCVA: Best corrected visual acuity, CMT: Central macular thickness  
P<sup>1</sup>:One way ANOVA between all groups , p<sup>2</sup>: General liner model for each group

**Table 3.** Comparison of intraocular pressure of treatment groups.


	Bevacizumab Group (IVB) (n:27)	Ranibizumab Group (IVR) (n:22)	Aflibercept Group (IVA) (n:20)	p <sup>1</sup>
Pre-IOP	16.96 ±1.02	16.41± 0.73	16.55 ±0.99	0.09
Post-IOP-month 1	16.63 ±0.79	16.14±0.99	16.80± 0.77	<b>0.04</b>
Post-IOP-month 3	17.26±1.13	16.09 ±1.02	17.05± 0.88	<b>0.001</b>
Post-IOP-month 6	16.70± 0.95	16.41± 0.91	16.75± 0.79	0.39
Post-IOP-month 9	15.81± 0.88	16.22± 1.34	16.50± 0.70	0.07
Post-IOP-month12	15.78± 0.97	15.95± 0.95	16.15± 0.81	0.40
p <sup>2</sup>	<b>0.06</b>	<b>0.08</b>	<b>0.07</b>	

IVB: Intravitreal bevacizumab, IVR: Intravitreal ranibizumab, IVA: Intravitreal aflibercept, IOP: Intraocular pressure  
p1:One way ANOVA between all groups, p2: General liner model for each group


mean number of injections was significantly higher in IVB, IVR groups and lower in IVA group ( $4.70 \pm 1.10$ ,  $4.05 \pm 0.99$ ,  $3.40 \pm 0.50$ ,  $p = 0.001$ , respectively). IOP was significantly lower in IVR group compared with other 2 groups at month 1 and 3 of treatment. BCVA was significantly improved in IVR and IVA groups, compared with the IVB group at month 6 of follow-up. Similarly, CMT was significantly lower in IVR and IVA groups, compared with the IVB group at month 6 of follow-up. Regarding BCVA, IOP and CMT values on month 12, there was no statistically significant difference between the 3 groups. Alterations in BCVA, IOP and CMT values of treatment groups in different time periods are shown in figures 1, 2 and 3.



**Fig. 1.** Alterations in BCVA at different time points among 3 treatment groups.



**Fig. 2.** Alterations in IOP at different time points among 3 treatment groups.



**Fig. 3.** Alterations in CMT at different time points among 3 treatment groups.

In this 12-months period, scatter laser treatment requirement at the end of month 6 was recorded. In IVB, IVR and IVA groups, the number of patients who required scatter laser treatment were 6 (22%), 4 (18.2%) and 4 (20%), respectively. There was no statistically significant difference between groups regarding scatter laser treatment requirement ( $p = 0.41$ ).

Side effects reported during this time period were also recorded. There were 2 transient ischemic attacks reported in IVB group (2/27, 7.4%) whereas 1 transient ischemic attack and 1 transient numbness on one half of the body reported in IVA group (2/20, 10%), and no side effect was reported in IVR group.

## DISCUSSION

Due to several side effects and limitations of previously described treatment modalities such as laser photocoagulation or intravitreal corticosteroid injections for ME secondary to BRVO, there is an emerging interest over intravitreal injections of anti-VEGF.<sup>8,9</sup> Up-to-date, three anti-VEGF agent have been evaluated, including bevacizumab, ranibizumab, aflibercept.<sup>10-12</sup> Bevacizumab (149 kDa) is a full-length humanized monoclonal immunoglobulin-G1 antibody that binds all isoforms of VEGF-A but it is not approved by Food and Drug Administration (FDA) for the treatment of ME secondary to BRVO.<sup>10</sup> Ranibizumab (48 kDa) is a recombinant humanized immunoglobulin G1 kappa iso-type antibody fragment that binds all isoforms of VEGF-A and is FDA approved for the treatment of ME secondary to BRVO.<sup>11</sup> Aflibercept (115 kDa) is a recombinant fusion protein consisting of the VEGF extracellular binding domains of the human VEGF receptors 1 and 2 fused to the Fc domain of human immunoglobulin-G1 and is FDA approved for the treatment of ME secondary to BRVO. In addition to binding VEGF, aflibercept also binds placental growth factors 1 and 2.<sup>12</sup> To best of our knowledge, this is first study that compares these 3 different anti-VEGF agents in the treatment of ME associated with BRVO, and one of the most important results of this study was that total number of injection was significantly lower in IVA group compared with the other groups. In addition, BCVA and CMT values were significantly improved in IVR and IVA groups, compared with the IVB group at month 6; but there was no statistically significant difference at the end of month 12. On the other hand, IOP values were better in IVR group compared with other 2 groups only at month 1 and 3 of treatment.

The data about the anti-VEGF treatment in ME due to BRVO is accumulating, especially in recent years. In a previous study, 24-months follow-up results of IVB has been investigated and complete resolution was reported in more than one-third of patients while partially resolved in other one third among 35 patients with ME associated with

BRVO and this is consistent with our findings.<sup>13</sup> Farinha et al. investigated long-term results ( $44.8 \pm 8.0$  months) of IVR treatment in BRVO and reported that visual acuity showed significant improvements with an average of 5.9 injections.<sup>14</sup> Our study yielded more injection numbers but the small injection number given by the Farina et al. may be due to less requirement of anti-VEGF after the first year of treatment. A recent study showed a good control of ME with monthly injections within six months of IVA following 8 weekly repetitions for 52 weeks as 3+ PRN treatment in our study.<sup>15</sup> In our study, three anti-VEGF agents were effective for the treatment of ME associated with BRVO within twelve months.

Although, the efficacies of intravitreal anti-VEGF agent injections were determined in the treatment of ME due to BRVO; the data comparing these agents is limited.<sup>13-15</sup> Regnier et al. compared the efficacy and safety of Ranibizumab 0.5 mg PRN, aflibercept 2 mg monthly, dexamethasone 0.7 mg implant, laser photocoagulation, ranibizumab plus laser, or sham intervention for ME secondary to BRVO and determined that there was no statistically significant difference between ranibizumab and aflibercept at month 6 or 12 based on visual acuity gain by letters and they were better than other treatment regimens investigated in this analysis.<sup>16</sup> In another recent study, Narayanan et al (MARVEL study) compared the efficacy and safety of intravitreal bevacizumab with ranibizumab in treatment of ME due to BRVO and determined that although both treatment groups had significant improvements in BCVA and reductions in CMT; there was no statistically significant difference between 2 groups at the end of month 6 of follow-up.<sup>17</sup> Son et al showed that both ranibizumab and bevacizumab are effective for the treatment of ME associated with BRVO, and both resulted in relatively equal anatomical and functional improvements at the end of 6 month 6 of follow-up.<sup>18</sup> However, in our study, both CMT and BCVA values were significantly improved in IVR and IVA groups compared with the IVB group at the end of month 6 of follow-up. There were no any significant differences between 3 groups at the end of the month 12.

When the line graphs of this study are analyzed, we can say that both BCVA and CMT lines were very similar for IVB, IVR and IVA groups at month 12. One of the differences between those 3 groups was the IOP levels, which were generally lower in IVR group at month 1 and 3 but the differences between those 3 groups did not reach statistically significant at months 6, 9 and 12. Another primary difference between those 3 groups was the total number of injections

number which was statistically significantly lower in IVA group. In retinal pigment epithelium/choroid organ cultures, aflibercept showed a prolonged VEGF inhibition (up to 59 days) compared to other VEGF antagonists, namely ranibizumab and bevacizumab.<sup>19</sup> On the other hand, there were some differences in line graphs of IVB group compared with other 2 groups. BCVA and CMT values had fluctuations at month 6 follow-up in IVB group which may be interpreted as a sign of one more injection requirement. We also determined a statistically significant difference between IVR or IVA groups and IVB group regarding total number of injection; however, Narayanan et al. and Son et al. failed to detect differences in total injection number of patients on ranibizumab and bevacizumab treatments at the end of month 6.<sup>17,18</sup> Hikichi et al. reported that with IVB injections, BCVA and CMT improved significantly at all time periods during 24 months of follow-up.<sup>20</sup> However, there were also fluctuations in both BCVA and CMT at month 3 of follow-up. However, Jaissle et al.<sup>21</sup> found no fluctuation in BCVA or CMT during the bevacizumab treatment for 24 months, with a mean injection number of 3.2. Regarding our data, we can suggest that the timing of the bevacizumab injections, especially during the first 6 months of the treatment, may be important in order to prevent those fluctuations.

There are some limitations of this study that should be mentioned. First is the retrospective design of the study that may result in some bias. Another drawback is the low number of patients. However, these results may shed light to further larger studies.

In conclusion, we have compared 3 different anti-VEGF agents in the treatment of ME due to BRVO and determined that, although IVR and IVA groups had better results in BCVA and CMT values at the month 6 of follow-up, there was no significant difference between 3 groups at the end of month 12. On the other hand, total injection number was significantly lower in IVA group than other 2 groups. These results suggest that when bevacizumab, ranibizumab, and aflibercept are placed into the human eye, the biological effects of the three agents are somewhat equivalent. Therefore, a study on the precise biological effects of anti-VEGF agents in the human eye should be carried out. Larger studies with longer follow-up periods are warranted to define the clinical differences of those commonly used anti-VEGF agents regarding not only efficacy but also the number of injections required.

## REFERENCES

1. Hahn P, Fekrat S. Best practices for treatment of retinal vein occlusion. *Curr Opin Ophthalmol* 2012;23:175-181.
2. Lee WJ, Kang MH, Seong M, et al. Comparison of aqueous concentrations of angiogenic and inflammatory cytokines in diabetic macular edema and macular edema due to branch retinal vein occlusion. *Br J Ophthalmology* 2012;96:1426-30.
3. Noma H, Funatsu H, Yamasaki M, et al. Aqueous humour levels of cytokines are correlated to vitreous levels and severity of macular edema in branch retinal vein occlusion. *Eye (Lond)* 2008;22:42-8.
4. The Branch Vein Occlusion Study Group. Argon laser photocoagulation for macular edema in branch vein occlusion. *Am J Ophthalmol* 1984;98:271-82.
5. Ahn SJ, Ahn J, Woo SJ, et al. Initial dose of three monthly intravitreal injections versus PRN intravitreal injections of bevacizumab for macular edema secondary to branch retinal vein occlusion. *Biomed Res Int* 2013;2013:209735.
6. Campochiaro PA, Heier JS, Feiner L, et al. Ranibizumab for macular edema following branch retinal vein occlusion: six-month primary end point results of a phase III study. *Ophthalmology* 2010;117:1102-1112.e1.
7. Campochiaro PA, Clark WL, Boyer DS, et al. Intravitreal aflibercept for macular edema following branch retinal vein occlusion: the 24-week results of the VIBRANT study. *Ophthalmology* 2015;122:538-544.
8. Fung AE, Bhisitkul RB. Safety monitoring with ocular anti-vascular endothelial growth factor therapies. *Br J Ophthalmol* 2008;92:1573-74.
9. Gillies MC, Simpson JM, Billson FA, et al. Safety of an intravitreal injection of triamcinolone: results from a randomized clinical trial. *Arch Ophthalmol* 2004;122:336-40.
10. Ferrara N, Hillan KJ, Gerber HP, et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. *Nat Rev Drug Discov* 2004;3:391-400.
11. Ferrara N, Damico L, Shams N, et al. Development of ranibizumab, an anti-vascular endothelial growth factor antigen binding fragment, as therapy for neovascular age-related macular degeneration. *Retina* 2006;26:859-70.
12. Holash J, Davis S, Papadopoulos N, et al. VEGF-Trap: a VEGF blocker with potent antitumor effects. *Proc Natl Acad Sci U S A* 2002;99:11393-98.
13. Tsagkatakis M, Papatomas T, Lythgoe D, et al. Twenty-Four-Month Results of Intravitreal Bevacizumab in Macular Edema Secondary to Branch Retinal Vein Occlusion. *Semin Ophthalmol* 2015;30:352-59.
14. Farinha C, Marques JP, Almeida E, et al. Treatment of Retinal Vein Occlusion with Ranibizumab in Clinical Practice: Longer-Term Results and Predictive Factors of Functional Outcome. *Ophthalmic Res* 2015;55:10-18.
15. Clark WL, Boyer DS, Heier JS, et al. Intravitreal Aflibercept for Macular Edema Following Branch Retinal Vein Occlusion: 52-Week Results of the VIBRANT Study. *Ophthalmology* 2016;123:330-36.
16. Regnier SA, Larsen M, Bezlyak V, et al. Comparative efficacy and safety of approved treatments for macular edema secondary to branch retinal vein occlusion: a network meta-analysis. *BMJ Open* 2015;5:e007527
17. Narayanan R, Panchal B, Das T, et al. A randomised, double-masked, controlled study of the efficacy and safety of intravitreal bevacizumab versus ranibizumab in the treatment of macular edema due to branch retinal vein occlusion: MARVEL Report No. 1. *Br J Ophthalmol* 2015;99:954-59.
18. Son BK, Kwak HW, Kim ES, et al. Comparison of Ranibizumab and Bevacizumab for Macular Edema Associated with Branch Retinal Vein Occlusion. *Korean J Ophthalmol* 2017;31:209-16.
19. Malik D, Tarek M, Caceres del Carpio J, et al. Safety profiles of anti-VEGF drugs: bevacizumab, ranibizumab, aflibercept and ziv-aflibercept on human retinal pigment epithelium cells in culture. *Br J Ophthalmol* 2014;98:i11-i16.
20. Hikichi T, Higuchi M, Matsushita T, et al. Two-year outcomes of intravitreal bevacizumab therapy for macular edema secondary to branch retinal vein occlusion. *Br J Ophthalmol* 2014;98:195-99.
21. Jaisle GB, Szurman P, Feltgen N, et al. Predictive factors for functional improvement after intravitreal bevacizumab therapy for macular edema due to branch retinal vein occlusion. *Graefes Arch Clin Exp Ophthalmol* 2011;249:183-92.